Bernstein SocGen Group Upgrades Ionis Pharmaceuticals (IONS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
June 17, 2024 6:21 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $70.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS)
The analyst comments "We hosted IONSs CEO and CFO for Boston/Baltimore NDR and the meetings strengthen our conviction that IONS is poised to successfully... More



